Şimşek, BetülDoğan, EsinKuzuluk, Didar GürsoyCemaloğlu, Mustafa2024-09-192024-09-1920231302-99401308-8491https://doi.org/10.26650/jchild.2023.1324273https://search.trdizin.gov.tr/tr/yayin/detay/1261656https://hdl.handle.net/20.500.12483/15853Dear Editor, Rhabdomyosarcoma (RMS) is a rare, aggressive, and malignant neoplasm with rapid growth composed of primitive mesenchymal cells that exhibit skeletal muscle differentiation and mainly affects children and adolescents (60%) [1]. RMS is the most common soft tissue sarcoma with a rate of 50-60% in pediatric patients and ranks third among pediatric extracranial solid tumors, following Wilms tumor and neuroblastoma at a rate of 4-5% [2]. Head and neck localizations constitute 35–40% of cases, with oral lesions being extremely rare [3].eninfo:eu-repo/semantics/openAccessLetter23439940010.26650/jchild.2023.13242731261656